AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
AstraZeneca has announced that Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the ...
EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...
Imfinzi in combination with chemotherapy has been recommended for approval in the European Union for the treatment of ...
This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...
AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for ...
Hosted on MSN1d
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last WeekAIM ImmunoTech surged in retail discussions after announcing the first new subject was dosed in Phase 2 of its Phase 1b/2 ...
Hosted on MSN12d
AstraZeneca Rises Almost 9% in a Month: How to Play the StockAstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
AstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...
AstraZeneca Pharma India receives CDSCO approval to import and distribute cancer treatment medicine Durvalumab solutions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback